Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer

NCT00738881 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

23

Enrollment

NIH

Sponsor class

Stopped Slow accrual

Conditions

Recurrent Non-Small Cell Lung Carcinoma
Stage IIIA Non-Small Cell Lung Cancer
Stage IIIB Non-Small Cell Lung Cancer
Stage IV Non-Small Cell Lung Cancer

Interventions

DRUG: Erlotinib Hydrochloride
DRUG: Pemetrexed Disodium

Sponsor

National Cancer Institute (NCI)

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]